ATE539063T1 - Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen - Google Patents

Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen

Info

Publication number
ATE539063T1
ATE539063T1 AT08759158T AT08759158T ATE539063T1 AT E539063 T1 ATE539063 T1 AT E539063T1 AT 08759158 T AT08759158 T AT 08759158T AT 08759158 T AT08759158 T AT 08759158T AT E539063 T1 ATE539063 T1 AT E539063T1
Authority
AT
Austria
Prior art keywords
regioselective
azabenzimidazoles
benzimidazoles
copper
catalyzed synthesis
Prior art date
Application number
AT08759158T
Other languages
German (de)
English (en)
Inventor
Jorge Alonso
Andreas Lindenschmidt
Marc Nazare
Matthias Urmann
Nis Halland
Kyek Omar R
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE539063T1 publication Critical patent/ATE539063T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08759158T 2007-06-26 2008-06-11 Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen ATE539063T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290800 2007-06-26
PCT/EP2008/004639 WO2009000413A1 (en) 2007-06-26 2008-06-11 A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles

Publications (1)

Publication Number Publication Date
ATE539063T1 true ATE539063T1 (de) 2012-01-15

Family

ID=38646504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08759158T ATE539063T1 (de) 2007-06-26 2008-06-11 Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen

Country Status (12)

Country Link
US (1) US8735586B2 (enExample)
EP (1) EP2173721B1 (enExample)
JP (1) JP5492770B2 (enExample)
KR (1) KR20100023907A (enExample)
CN (1) CN101687815A (enExample)
AT (1) ATE539063T1 (enExample)
AU (1) AU2008267444A1 (enExample)
BR (1) BRPI0813271A2 (enExample)
CA (1) CA2691857A1 (enExample)
IL (1) IL202823A0 (enExample)
MX (1) MX2009013753A (enExample)
WO (1) WO2009000413A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CA2785536C (en) 2009-12-30 2018-02-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
KR20130059400A (ko) 2010-08-25 2013-06-05 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
US9388140B2 (en) 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
US8609688B2 (en) 2011-06-24 2013-12-17 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2013191188A1 (ja) * 2012-06-22 2013-12-27 住友化学株式会社 縮合複素環化合物
CN102924460B (zh) * 2012-11-05 2015-12-16 南京师范大学 一种4H-吡咯并[1,2-a]苯并咪唑衍生物及其合成方法和应用
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
CN103130811B (zh) * 2013-03-11 2015-02-25 河南师范大学 一种5,6-二氢吡唑并[1,5-c]喹唑啉类化合物的合成方法
CN105189495A (zh) * 2013-03-15 2015-12-23 先正达参股股份有限公司 新颖的杀微生物剂
US9682971B2 (en) 2013-03-15 2017-06-20 Janssen Pharmaceutica Nv 1,2,5-Substituted benzimidazoles as flap modulators
US8952177B2 (en) 2013-03-15 2015-02-10 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as FLAP modulators
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規キナゾリノン
WO2015077572A1 (en) 2013-11-22 2015-05-28 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
CN103965136B (zh) * 2014-05-07 2016-09-07 苏州波菲特新材料科技有限公司 一种制备n-甲基噻唑啉-2-酮类化合物的方法
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CN108473495B (zh) 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
CN106519250A (zh) * 2016-09-29 2017-03-22 辽宁石油化工大学 含氮小分子有机配体调节荧光发射性质的一维链状铜配位聚合物的制备方法
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7227157B2 (ja) 2016-12-29 2023-02-21 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
MX388196B (es) 2017-04-26 2025-03-19 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
TWI795440B (zh) 2017-09-15 2023-03-11 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
GB201800688D0 (en) 2018-01-16 2018-02-28 Redag Crop Prot Ltd Agricultural chemicals
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
US10870648B2 (en) 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020190791A1 (en) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
CN110982806B (zh) * 2019-08-30 2022-09-02 浙江工业大学 一种蛋白质芳基衍生物及其制备方法
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
CN111206260B (zh) * 2020-02-12 2022-03-22 齐鲁工业大学 一种吡啶并[1,2-a]苯并咪唑类化合物的电化学合成方法
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101088247B1 (ko) * 2005-12-19 2011-11-30 라퀄리아 파마 인코포레이티드 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
AU2007329548A1 (en) * 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Also Published As

Publication number Publication date
US20100261909A1 (en) 2010-10-14
EP2173721B1 (en) 2011-12-28
JP2010531313A (ja) 2010-09-24
EP2173721A1 (en) 2010-04-14
KR20100023907A (ko) 2010-03-04
MX2009013753A (es) 2010-01-26
CN101687815A (zh) 2010-03-31
WO2009000413A1 (en) 2008-12-31
BRPI0813271A2 (pt) 2014-12-30
JP5492770B2 (ja) 2014-05-14
AU2008267444A1 (en) 2008-12-31
IL202823A0 (en) 2010-06-30
US8735586B2 (en) 2014-05-27
CA2691857A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ATE539063T1 (de) Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen
BRPI0813273A2 (pt) Síntese catalisada por metal regiosseletivo de benzimidazóis e azabenzimidazóis anelados
NO20090264L (no) En regioselektiv palladiumkatalysert syntese av benzimidazoler og azabenzimidazoler
ATE511501T1 (de) Übergangsmetallkatalysierte synthese von 2h- indazolen
EA201171211A1 (ru) Производные оксадиазола
EA201070238A1 (ru) Соединения пиримидина
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
EA201070422A1 (ru) Производные оксадиазола
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MX2009006730A (es) Derivados de n-(5, 6, 7, 8-tetrahidronaftalen-1-il) urea y compuestos relacionados como antagonistas de receptor vaniloide trpv1 par el tratamiento de dolor.
EA201070423A1 (ru) Диарильные соединения оксадиазолов
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
ATE537142T1 (de) Übergangsmetallkatalysierte synthese von n- aminoindolen
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
CR10771A (es) Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f] indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
EA201070779A1 (ru) Триазолсодержащие производные оксадиазола
MX2010007019A (es) Compuestos de bencimidazol.
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
PH12012501125A1 (en) 3, 4, 4a, 10b - tetrahydro -1h- thiopyrano -[4, 3-c] isoquinoline derivatives
MA32788B1 (fr) 1-(arylsulfonyl)-4-(piperazine-1-yl)-1h-benzimidazoles servant de ligands de la 5-hydroxytryptamine-6
BRPI0812829A2 (pt) Processo para o acoplamento catalisado por paládio de alcinas terminais com tosilatos de arila